Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – KewalRamani Website

Vineet N. KewalRamani, Ph.D.

Selected Publications

1)  Maertens GN, Cook NJ, Wang W, Hare S, Gupta SS, Oztop I, Lee K, Pye VE, Cosnefroy O, Snijders AP, Kewalramani VN, Fassati A, Engelman A, Cherepanov P.
Structural basis for nuclear import of splicing factors by human Transportin 3.
Proc. Natl. Acad. Sci. U.S.A. 111: 2728-33, 2014.
2)  Koh Y, Wu X, Ferris AL, Matreyek KA, Smith SJ, Lee K, Kewalramani VN, Hughes SH, Engelman A.
Differential Effects of Human Immunodeficiency Virus Type 1 Capsid and Cellular Factors Nucleoporin 153 and LEDGF/p75 on the Efficiency and Specificity of Viral DNA Integration.
J. Virol. 87: 648-58, 2013.
3)  Price AJ, Fletcher AJ, Schaller T, Elliott T, Lee K, Kewalramani VN, Chin JW, Towers GJ, James LC.
CPSF6 Defines a Conserved Capsid Interface that Modulates HIV-1 Replication.
PLoS Pathog. 8: e1002896, 2012.
4)  Ambrose Z, Lee K, Ndjomou J, Xu H, Oztop I, Matous J, Takemura T, Unutmaz D, Engelman A, Hughes SH, Kewalramani VN.
Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection.
J. Virol. 86: 4708-14, 2012.
5)  Lee K, Mulky A, Yuen W, Martin TD, Meyerson NR, Choi L, Yu H, Sawyer SL, Kewalramani VN.
HIV-1 capsid-targeting domain of cleavage and polyadenylation specificity factor 6.
J Virol. 3851-60, 2012.
6)  Lee K, Ambrose Z, Martin T, Oztop I, Mulky A, Julias J, Vandegraaff N, Baumann J, Wang R, Yuen W, Takemura T, Shelton K, Taniuchi I, Li Y, Sodroski J, Littman D, Coffin J, Hughes S, Unutmaz D, Engelman A, KewalRamani V.
Flexible use of nuclear import pathways by HIV-1.
Cell Host Microbe. 7: 221-233, 2010.
7)  Del Prete GQ, Kearney MF, Spindler J, Wiegand A, Chertova E, Roser JD, Estes JD, Hao XP, Trubey CM, Lara A, Lee K, Chaipan C, Bess JW, Nagashima K, Keele BF, Macallister R, Smedley J, Pathak VK, Kewalramani VN, Coffin JM, Lifson JD.
Restricted replication of xenotropic murine leukemia virus-related virus in pigtailed macaques.
J. Virol. 86: 3152-66, 2012.
8)  Boltz VF, Ambrose Z, Kearney MF, Shao W, Kewalramani VN, Maldarelli F, Mellors JW, Coffin JM.
Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase.
J. Virol. 86: 12525-30, 2012.
9)  Kearney M, Spindler J, Shao W, Maldarelli F, Palmer S, Hu SL, Lifson JD, Kewalramani VN, Mellors JW, Coffin JM, Ambrose Z.
Genetic Diversity of Simian Immunodeficiency Virus Encoding HIV-1 Reverse Transcriptase Persists in Macaques despite Antiretroviral Therapy.
J. Virol. 85: 1067-76, 2011.
10)  Schaller T, Ocwieja KE, Rasaiyaah J, Price AJ, Brady TL, Roth SL, Hué S, Fletcher AJ, Lee K, Kewalramani VN, Noursadeghi M, Jenner RG, James LC, Bushman FD, Towers GJ.
HIV-1 Capsid-Cyclophilin Interactions Determine Nuclear Import Pathway, Integration Targeting and Replication Efficiency.
PLoS Pathog. 7: e1002439, 2011.
11)  Furtak V, Mulky A, Rawlings SA, Kozhaya L, Lee K, Kewalramani VN, Unutmaz D.
Perturbation of the P-Body Component Mov10 Inhibits HIV-1 Infectivity.
PLoS ONE. 5: e9081, 2010.
12)  Shao W, Kearney M, Maldarelli F, Mellors JW, Stephens RM, Lifson JD, KewalRamani VN, Ambrose Z, Coffin JM, Palmer SE.
RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy.
Retrovirology. 6: 101, 2009.
13)  Krishnan L, Matreyek KA, Oztop I, Lee K, Tipper CH, Li X, Dar MJ, Kewalramani VN, Engelman A.
The Requirement for Cellular Transportin 3 (TNPO3 or TRN-SR2) during Infection Maps to Human Immunodeficiency Virus Type 1 Capsid and Not Integrase.
J. Virol. 84: 397-406, 2010.
14)  Chung NP, Breun SK, Bashirova A, Baumann JG, Martin TD, Karamchandani JM, Rausch JW, Le Grice SF, Wu L, Carrington M, Kewalramani VN.
HIV-1 transmission by dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) is regulated by determinants in the carbohydrate recognition domain that are absent in liver/lymph node-SIGN (L-SIGN).
J. Biol. Chem. 285: 2100-2112, 2010.
15)  Hatziioannou T, Ambrose Z, Chung NP, Piatak M, Yuan F, Trubey CM, Coalter V, Kiser R, Schneider D, Smedley J, Pung R, Gathuka M, Estes JD, Veazey RS, KewalRamani VN, Lifson JD, Bieniasz PD.
A macaque model of HIV-1 infection.
Proc. Natl. Acad. Sci. U.S.A. 106: 4425-9, 2009.
16)  Michel N, Goffinet C, Ganter K, Allespach I, Kewalramani VN, Saifuddin M, Littman DR, Greene WC, Goldsmith MA, Keppler OT.
Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo.
Retrovirology. 6: 2, 2009.
17)  Ambrose Z, Compton L, Piatak M, Lu D, Alvord WG, Lubomirski MS, Hildreth JE, Lifson JD, Miller CJ, KewalRamani VN.
Incomplete protection against simian immunodeficiency virus vaginal transmission in rhesus macaques by a topical antiviral agent revealed by repeat challenges.
J. Virol. 82: 6591-9, 2008.
18)  Mulky A, Cohen TV, Kozlov SV, Korbei B, Foisner R, Stewart CL, KewalRamani VN.
The LEM domain proteins emerin and LAP2alpha are dispensable for human immunodeficiency virus type 1 and murine leukemia virus infections.
J. Virol. 82: 5860-8, 2008.
19)  Ambrose Z, KewalRamani V.
Of mice and monkeys: New advances in animal models to study HIV-1 therapy and prophylaxis.
Future HIV Ther. 2: 363-373, 2008.
Full Text Article. [Journal]
20)  Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, Flanary L, Oswald K, Piatak M, Smedley J, Shao W, Bischofberger N, Maldarelli F, Kimata JT, Mellors JW, Hu SL, Coffin JM, Lifson JD, KewalRamani VN.
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.
J. Virol. 81: 12145-55, 2007.
21)  Ambrose Z, Kewalramani VN, Bieniasz PD, Hatziioannou T.
HIV/AIDS: in search of an animal model.
Trends Biotechnol. 25: 333-7, 2007.
22)  Wang JH, Janas AM, Olson WJ, KewalRamani VN, Wu L.
CD4 coexpression regulates DC-SIGN-mediated transmission of human immunodeficiency virus type 1.
J. Virol. 81: 2497-507, 2007.
23)  Wu L, KewalRamani VN.
Dendritic-cell interactions with HIV: infection and viral dissemination.
Nat. Rev. Immunol. 6: 859-68, 2006.
24)  Ambrose Z, Julias JG, Boyer PL, Kewalramani VN, Hughes SH.
The Level of Reverse Transcriptase (RT) in Human Immunodeficiency Virus Type 1 Particles Affects Susceptibility to Nonnucleoside RT Inhibitors but Not to Lamivudine.
J Virol. 80: 2578-81, 2006.
25)  Sun J, Soos T, Kewalramani VN, Osiecki K, Zheng JH, Falkin L, Santambrogio L, Littman DR, Goldstein H.
CD4-specific transgenic expression of human cyclin T1 markedly increases human immunodeficiency virus type 1 (HIV-1) production by CD4+ T lymphocytes and myeloid cells in mice transgenic for a provirus encoding a monocyte-tropic HIV-1 isolate.
J. Virol. 80: 1850-62, 2006.
26)  García-Piñeres AJ, Hildesheim A, Trivett M, Williams M, Wu L, Kewalramani VN, Pinto LA.
Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine.
Eur. J. Immunol. 36: 437-45, 2006.
27)  VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.
Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.
J Virol. 79: 11598-606, 2005.
28)  Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes SH, Kewalramani VN.
In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
J Virol. 78: 13553-61, 2004.
29)  Baumann JG, Unutmaz D, Miller MD, Breun SK, Grill SM, Mirro J, Littman DR, Rein A, KewalRamani VN.
Murine T cells potently restrict human immunodeficiency virus infection.
J Virol. 78: 12537-47, 2004.
30)  Lee K, KewalRamani VN.
From the Cover: In defense of the cell: TRIM5{alpha} interception of mammalian retroviruses.
Proc Natl Acad Sci U S A. 101: 10496-10497, 2004.
31)  Wu L, Martin TD, Han YC, Breun SK, KewalRamani VN.
Trans-dominant cellular inhibition of DC-SIGN-mediated HIV-1 transmission.
Retrovirology. 1: 14, 2004.
32)  Rawat SS, Gallo SA, Eaton J, Martin TD, Ablan S, KewalRamani VN, Wang JM, Blumenthal R, Puri A.
Elevated expression of GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus type 1 fusion.
J. Virol. 78: 7360-8, 2004.
33)  Rawat SS, Eaton J, Gallo SA, Martin TD, Ablan S, Ratnayake S, Viard M, KewalRamani VN, Wang JM, Blumenthal R, Puri A.
Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion.
Virology. 318: 55-65, 2004.
34)  Wu L, Martin TD, Carrington M, KewalRamani VN.
Raji B cells, misidentified as THP-1 cells, stimulate DC-SIGN-mediated HIV transmission.
Virology. 318: 17-23, 2004.
35)  Dang Q, Chen J, Unutmaz D, Coffin JM, Pathak VK, Powell D, KewalRamani VN, Maldarelli F, Hu WS.
Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways.
Proc. Natl. Acad. Sci. U.S.A. 101: 632-7, 2004.
36)  KewalRamani VN, Coffin JM.
Weapons of mutational destruction.
Science. 301: 923-925, 2003.
37)  McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ.
Recruitment of HIV and its receptors to dendritic cell-T cell junctions.
Science. 300: 1295-7, 2003.
38)  Bashirova AA, Wu L, Cheng J, Martin TD, Martin MP, Benveniste RE, Lifson JD, KewalRamani VN, Hughes A, Carrington M.
Novel member of the CD209 (DC-SIGN) gene family in primates.
J. Virol. 77: 217-27, 2003.
39)  Gummuluru S, KewalRamani VN, Emerman M.
Dendritic cell-mediated viral transfer to T cells is required for human immunodeficiency virus type 1 persistence in the face of rapid cell turnover.
J Virol. 76: 10692-701, 2002.
40)  Wu L, Martin TD, Vazeux R, Unutmaz D, KewalRamani VN.
Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission.
J Virol. 76: 5905-14, 2002.
41)  Wu L, Bashirova AA, Martin TD, Villamide L, Mehlhop E, Chertov AO, Unutmaz D, Pope M, Carrington M, KewalRamani VN.
Rhesus macaque dendritic cells efficiently transmit primate lentiviruses independently of DC-SIGN.
Proc Natl Acad Sci U S A. 99: 1568-73, 2002.
42)  Bashirova AA, Geijtenbeek TB, van Duijnhoven GC, van Vliet SJ, Eilering JB, Martin MP, Wu L, Martin TD, Viebig N, Knolle PA, KewalRamani VN, van Kooyk Y, Carrington M.
A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection.
J Exp Med. 193: 671-8, 2001.
43)  Browning CM, Smith MJ, Clark NM, Lane BR, Parada C, Montano M, KewalRamani VN, Littman DR, Essex M, Roeder RG, Markovitz DM.
Human GLI-2 is a tat activation response element-independent Tat cofactor.
J Virol. 75: 2314-23, 2001.
44)  Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y.
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.
Cell. 100: 587-97, 2000.
45)  Unutmaz D, KewalRamani VN, Marmon S, Littman DR.
Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.
J. Exp. Med. 189: 1735-46, 1999.
46)  Mörner A, Björndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, Thorstensson R, Fenyö EM, Björling E.
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.
J. Virol. 73: 2343-9, 1999.
47)  Kimata JT, Gosink JJ, KewalRamani VN, Rudensey LM, Littman DR, Overbaugh J.
Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne.
J. Virol. 73: 1655-60, 1999.
48)  Garber ME, Wei P, KewalRamani VN, Mayall TP, Herrmann CH, Rice AP, Littman DR, Jones KA.
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein.
Genes Dev. 12: 3512-27, 1998.
49)  Zhang YJ, Dragic T, Cao Y, Kostrikis L, Kwon DS, Littman DR, KewalRamani VN, Moore JP.
Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro.
J. Virol. 72: 9337-44, 1998.
50)  Cecilia D, KewalRamani VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, Zolla-Pazner S.
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.
J. Virol. 72: 6988-96, 1998.
51)  Langlois AJ, Desrosiers RC, Lewis MG, KewalRamani VN, Littman DR, Zhou JY, Manson K, Wyand MS, Bolognesi DP, Montefiori DC.
Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.
J. Virol. 72: 6950-5, 1998.
52)  Unutmaz D, KewalRamani VN, Littman DR.
G protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions and on the utility of animal models.
Semin. Immunol. 10: 225-36, 1998.
53)  Michael NL, Nelson JA, KewalRamani VN, Chang G, O'Brien SJ, Mascola JR, Volsky B, Louder M, White GC, Littman DR, Swanstrom R, O'Brien TR.
Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.
J. Virol. 72: 6040-7, 1998.
54)  Trkola A, Ketas T, Kewalramani VN, Endorf F, Binley JM, Katinger H, Robinson J, Littman DR, Moore JP.
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
J. Virol. 72: 1876-85, 1998.
55)  Hill CM, Deng H, Unutmaz D, Kewalramani VN, Bastiani L, Gorny MK, Zolla-Pazner S, Littman DR.
Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.
J. Virol. 71: 6296-304, 1997.
56)  Deng HK, Unutmaz D, KewalRamani VN, Littman DR.
Expression cloning of new receptors used by simian and human immunodeficiency viruses.
Nature. 388: 296-300, 1997.
57)  Kewalramani VN, Park CS, Gallombardo PA, Emerman M.
Protein stability influences human immunodeficiency virus type 2 Vpr virion incorporation and cell cycle effect.
Virology. 218: 326-34, 1996.
58)  Kewalramani VN, Emerman M.
Vpx association with mature core structures of HIV-2.
Virology. 218: 159-68, 1996.
59)  Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M.
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
Proc. Natl. Acad. Sci. U.S.A. 91: 7311-5, 1994.
60)  Kewalramani VN, Panganiban AT, Emerman M.
Spleen necrosis virus, an avian immunosuppressive retrovirus, shares a receptor with the type D simian retroviruses.
J. Virol. 66: 3026-31, 1992.
Click Here to View Collapsed Bibliography.

This page was last updated on 2/21/2014.